Key result
EPCR occupancy by PC-S195A switches thrombin-mediated PAR-1 signaling to a barrier-protective endothelial response.
Why the study?
Does occupancy of endothelial protein C receptor (EPCR) by its natural ligand switch the protease activated receptor 1 (PAR-1)-dependent signaling specificity of thrombin from a proinflammatory/barrier-disruptive effect to a cytoprotective/barrier-protective effect in human pulmonary artery endothelial cells?
Does occupancy of endothelial protein C receptor (EPCR) by its natural ligand switch the protease activated receptor 1 (PAR-1)-dependent signaling specificity of thrombin from a proinflammatory/barrier-disruptive effect to a cytoprotective/barrier-protective effect in human pulmonary artery endothelial cells?
Ligand occupancy of EPCR switches thrombin-mediated PAR-1 signaling from barrier-disruptive to cytoprotective in human pulmonary artery endothelial cells, suggesting that systemic thrombin inhibition may not be an optimal strategy for treating inflammatory vascular disorders.
Answers are grounded in this paper and cite their sources.
EPCR occupancy may redirect thrombin-PAR-1 effects toward endothelial protection in vitro; leaves open translation to vascular inflammation therapies.
We recently demonstrated that the occupancy of endothelial protein C receptor (EPCR) by its natural ligand activated protein C (APC)/protein C switches the protease activated receptor 1 (PAR-1)-dependent signaling specificity of thrombin from a disruptive to a protective effect in cultured human umbilical vein endothelial cells. Given the phenotypic differences between endothelial cells in venular and arterial beds, in this study we evaluated the signaling function of thrombin in human pulmonary artery endothelial cells (HPAECs) before and after treating them with PC-S195A which lacks catalytic activity but exhibits a normal affinity for EPCR. As expected, both thrombin and thrombin receptor agonist peptide (TRAP) enhanced the permeability barrier of HPAECs; however, both PAR-1 agonists exhibited a potent barrier protective effect when the cells were treated with PC-S195A prior to stimulation by the agonists. Interestingly, similar to APC, thrombin exhibited a potent cytoprotective activity in the LPS-induced permeability and TNF-alpha-induced apoptosis and adhesion assays in the PC-S195A treated HPAECs. Treatment of HPAECs with the cholesterol depleting molecule methyl-beta-cyclodextrin eliminated the protective effect of both APC and thrombin. These results suggest that the occupancy of EPCR by its natural ligand recruits PAR-1 to a protective signaling pathway within lipid rafts of HPAECs. Based on these results we conclude that the activation of PAR-1 by thrombin would initiate a protective response in intact arterial vascular cells expressing EPCR. These findings may have important ramifications for understanding the mechanism of the participation of the vascular PAR-1 in pathophysiology of the inflammatory disorders.
No takes yet. Share an insight, caveat, or question.
Bae et al. (2008) studied Endothelial barrier dysfunction and vascular inflammation (in vitro model). Thrombin or thrombin receptor agonist peptide (TRAP) with catalytically inactive protein C (PC-S195A) or activated protein C (APC) vs. Thrombin or TRAP stimulation without prior PC-S195A occupancy of EPCR, or untreated control monolayers was evaluated on Endothelial cell barrier permeability, TNF-alpha-induced apoptosis, and THP-1 monocytic cell adhesion. Occupancy of EPCR by PC-S195A switches PAR-1 activation by thrombin (optimal at 5 nM) from a barrier-disruptive to a barrier-protective and cytoprotective response in HPAECs.
Synapse has enriched 10 related papers. Consider them for comparative context: